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Abstract:  
Aim: Evaluating solid lipid nanoparticles (INH-SLNs) for ocular delivery of isoniazid. 
Materials & methods: Characterized of INH-SLNs for morphological, thermal, crystallinity 
and NMR studies. In vitro release and ex-vivo corneal permeability studies were conducted. 
Proof-of-concept uptake studies using fluorescein-labelled SLNs (F-SLNs), in corneal and 
conjunctival cell lines and in eye. Antimycobacterial activity of INH-SLNs was confirmed. In 
vivo aqueous humor pharmacokinetics, toxicity and tolerance was performed in rabbit eye. 
Results: INH-SLNs showed extended release (48 h); enhanced corneal permeability (1.6 
times); 5 times lower MIC; significant uptake of F-SLNs in corneal and conjunctival cells 
and ocular tissues; 4.2 times improvement in ocular bioavailability (AUC) and in vivo acute 
and repeat dose safety.    
Conclusion: INH-SLNs is an effective ocular delivery system.  
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Introduction 
Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis 
which commonly affects the lungs. Extrapulmonary TB including orbital and external eye 
disease, represented 15% of 6.3 million cases that were notified in 2016  [1]. The precise 
incidence of ocular TB is however difficult to discern; ranging from 1.4% to 18% in 
various studies [2-4]. Ocular TB may primarily be a result of direct inoculation and or due 
to entry of the Mycobacterium into ocular surface and also delayed hypersensitivity 
reaction to the Mycobacterium protein [5]. TB of the eyes mostly affects the ciliary body 
and choroid due to the high regional oxygen tension of these tissues. Uveitis, especially 
posterior uveitis, is the most common form of intraocular TB. The most common clinical 
presentation appears to be posterior uveitis, followed by anterior uveitis, panuveitis, and 
intermediate uveitis [6]. Due to the complex nature of the eye including various 
anatomical and physiological barriers, significant challenges are involved in its treatment 
[7]. Presently the ocular TB treatment is similar to the systemic treatment option which 
involves 6-month oral therapy of four first-line drugs: isoniazid, rifampicin, ethambutol 
and pyrazinamide [8]. No better agent than the available options has been discovered for 
TB in the recent past, despite significant efforts.  
Isoniazid (INH) is a potent bactericidal agent and the most frequently used candidate for 
ocular TB treatment and recommended by WHO for the management of all forms of TB. 
It is a Biopharmaceutical Classification System (BCS)-class III drug (high solubility and 
low permeability) showing an aqueous solubility of 140 mg/ml and log P of -0.64. It 
However, hepatotoxicity and neurotoxicity associated with its systemic and prolonged use 
is a concern [9] . 
The most logical option to overcome these undesired systemic side effects of INH is to 
deliver the drug locally to the eye. However, the highly impermeable milieu of the eye 
especially the corneal surface and the factors like pre-corneal loss due to blinking, rapid 
washout by tears, drainage through the naso-lacrimal duct, and non-productive absorption 
limit successful therapy.  
Solid lipid nanoparticles (SLNs) have attracted an enormous interest in recent years as an 
ocular drug delivery option. In our previous works, we developed INH-SLNs which 
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modified the pharmacokinetic distribution of INH in plasma and brain following oral 
administration [10]. A 6 times improvement in plasma bioavailability and 4 times increase 
in brain bioavailability was observed with respect to free drug. 
Presently INH-SLN was evaluated for its suitability to deliver INH in to the eye following 
topical application as drops. The drug loading of INH in presently prepared SLNs was 
increased to 40% with respect to the lipid matrix to produce a concentrated dispersion 
which can deliver significant amount in a drop. In vitro release, ex vivo corneal 
permeability, and in vivo ocular pharmacokinetic profile of INH-SLNs was compared with 
the corresponding free drug solution. A fluorescein-labelled SLN system was used to 
confirm capacity of developed SLNs to reach internal eye tissues. The uptake of developed 
SLN formulation into corneal and conjunctival cells was also confirmed. AFM, TEM, 
DSC, FTIR, XRD and NMR studies in addition to particle size and zeta potential 
determination were done to describe the developed INH-SLN system. 
Two tier safety as (i) cytotoxicity and (ii) in vivo (a) acute dose and (b) 7 days repeat-dose 
ocular toxicity (following dermal toxicity) was established in rabbits, as per OECD 
guidelines. Stability studies were also conducted on the aqueous INH-SLN dispersions. 
MIC and in vitro antimycobacterial activity of INH-SLNs versus free INH was also 
determined. 
 
Materials and methods 
 
Materials 
Isoniazid was bought from Sigma Aldrich USA, and soy lecithin (Phospholipon
®
 90H) 
was received as a gift sample from Lipoid GmbH, Germany. Compritol 888 ATO
®
 was 
a gift sample from Gattefosse India Pvt Ltd. Stearic acid and Tween 80 were purchased 
from Central Drug House, Mumbai. All other chemicals and solvents used in the study 
were of analytical or HPLC grade. 
 
    Methods 
Preparation of INH-SLNs 
Solid lipid nanoparticles of isoniazid (INH) were prepared by the microemulsification 
method [11]. Briefly the lipidic phase (Compritol 888 ATO
® 
and Stearic acid (4:1) – 
Combi lipid) and the aqueous phase (polysorbate 80, soy lecithin and water) 
containing dissolved INH were heated to ∼10°C above the lipid melt temperature. 
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The proportion of surfactant and the volumes of two phases were so adjusted that a 
microemulsion was formed spontaneously upon mixing the two phases. Hot 
microemulsion, thus formed was transferred to an equal volume of cold water (∼2°C) 
under constant stirring (WiseTis HG-15 D, 10,000 rpm) to obtain SLNs. The prepared 
SLNs were used as such for further studies without dialysing the unentrapped INH. 
Note: - Fluorescein sodium loaded SLNs (F-SLNs) were also prepared similarly 
except that INH was replaced with fluorescein sodium.  Free fluorescein was removed 
from the system by dialysis prior to application. 
 
In vitro release studies 
In vitro release was performed using a glass tube open at both the ends with a dialysis 
membrane tied on its one side. A fixed quantity (3 ml) INH-SLNs or INH solution 
(INH-SOL), equivalent to 40 mg INH, was loaded on the dialysis membrane inside of 
the tube. This side of the tube (donor side) was dipped in 80 ml of dialysate 
comprising pH 7.2 phosphate buffer (20 mM) at 37 ºC. The dialysis membrane 
(12000 cut-off) was soaked in distilled water for 12 h prior to use. Suitable aliquots (3 
ml) of dialysate were withdrawn from time to time and replaced with fresh solution. 
The samples were quantified by HPLC, as described below in section. The cumulative 
drug released was calculated and expressed as a percentage of the theoretical 
maximum drug content. Model fitting was performed in order to select the best fit 
model describing the release of INH from its SLN dispersion. 
 
Ex-vivo, porcine cornea permeability studies                                                                                           
Freshly procured porcine cornea was mounted on a previously described diffusion cell 
[12]. The receptor compartment comprised of freshly prepared glutathione 
bicarbonate ringer (GBR) as the diffusion medium (20 ±2 ml), stirred continuously 
(50 rpm) at 37±0.2 
o
C. INH-SLNs and INH-SOL (aqueous solution of pristine INH at 
same concentration as INH-SLNs) (0.5 ml) placed on the porcine cornea represent the 
donor side. Samples were withdrawn at various time points with replacement and 
were analyzed by the developed HPLC method after suitable dilution. The apparent 
corneal permeability coefficient (Papp) and steady state flux of both INH-SLNs and 
INH-SOL were determined, as reported previously [13]. 
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  Stability study 
INH-SLNs was stored in tightly closed, screw capped vials, at 2-8 ºC for 6 and 12 
month. Samples were withdrawn and analyzed for particle size, total drug content, 
FTIR, XRD and DSC.  
Proof-of- concept studies: confocal microscopy 
A drop (30 µl) of the fluorescein labelled SLNs (F-SLNs) was administered into the 
fornix of the right eye of rats. Animals were sacrificed at 15 min, 4 h, 8 h and 24 h 
post instillation of the formulation. Eyes were enucleated immediately and stored at 
-20 °C. The eyes were embedded in cryomatrixTM before sectioning, and the 
samples were sliced into 10 µm thick sections using a cryostat (IEC Minotome 3398, 
American Instrument Exchange, Inc., Massachusetts, USA). Sections were then 
fixed onto slides. The complete eye sections were observed under confocal 
microscope (Nikon A1R, Japan) in fluorescent mode (Olympus FV3000) using 1.5X 
and 10X objective, and a 60X oil immersion objective. The images were processed 
by NIS-viewer software and fluorescent intensity was obtained using image J 
software. 
Cellular uptake studies 
Stratified HCLE (human corneal-limbal epithelial), and HCJE (human conjunctival 
epithelial) cell lines were maintained in 50% Dulbecco's Modified Eagles Medium 
(DMEM) and 50% F12 medium supplemented with 10% fetal calf serum (FCS), 100 
U/ml penicillin G and 100 µg/ml streptomycin, in a humidified incubator at 37 °C in 
5% CO2.  Cells were grown on coverslip and incubated with fluorescein labelled 
SLNs (F- SLNs), and an equivalent free fluorescein solution in standard medium for 
2 h. Cells were then washed, fixed and coverslips mounted according to routine 
immunocytochemistry methods. 
Minimum inhibitory concentration 
Minimum inhibitory concentration (MIC) of INH, Blank-SLNs and INH-SLNs was 
determined against M. tuberculosis H37Rv (ATCC 25618). Sterile agar media was 
mixed with 2 ml of M. tuberculosis H37Rv (2.5 × 10
7
 CFU/ml) containing various 
concentrations of free INH or Blank or INH-SLN formulations. The mixture was 
poured into 85 mm diameter petri dishes (approx. 30 ml each) and allowed to 
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solidify. All serial dilutions were made using sterile milli-Q water. The MIC was 
determined as lowest concentration causing no visible growth of H37Rv after 
incubation. 
Susceptibility test against M. tuberculosis 
M. tuberculosis H37Rv was grown to logarithmic phase (equivalent to OD595 ~ 0.5) 
in Middlebrook 7H9 broth (Difco Laboratory, USA) supplemented with albumin 
dextrose complex (Difco Laboratory, USA) for stock preparation. The bacterium 
was sub-cultured under aerobic condition in the same media from the stock at 37 ºC. 
Susceptibility test was performed by proportion method as reported earlier with 
slight modification [14, 15]. This method determines the percent growth (number of 
colonies) of a defined inoculum on control media (free from drug) versus growth of 
culture on media containing test sample (in critical amount) supposed to inhibit 
tuberculosis strain Rv. LJ media was inoculated (one loopful equivalent to 6.0 µl) 
with previously grown culture and incubated at 37 ºC for 6 weeks. Isolated colonies 
were picked and dispersed in water for injection (2 ml) to achieve a suspension 
equivalent to McFarland standard 1.0. The suspension was vortexed for 1 min to get 
a homogeneous culture and left for some time to remove any entrapped air bubbles. 
Standard dilution of 10
-4
 was prepared to inoculate the LJ media contained in 
McCartney vial. Control vial and vial containing SLNs were inoculated with same 
dilution (10
-4
) and incubated overnight in a slant position with loosened cap at 37 ◦C. 
After 12 h of incubation (overnight), the cap was tightened and incubation was 
continued for period of 6 weeks in upright position, although susceptibility was also 
assessed on 28
th
 day. The absence of colonies will confirm susceptibility of Rv strain 
to the treatment. The experiment was performed in Class II Biological Safety 
Cabinet and taking all care of infection. 
 
High performance liquid chromatography (HPLC) analysis of Isoniazid 
The determination of INH was carried out using a HPLC system (waters, alliance 
separation module e2695). A reversed phase X Bridge™ C18 column (250 mm × 4.6 
mm, 5 µm; Waters, USA) was used. Phosphate buffer solution (20 mM)/Acetonitrile 
(98:2, isocratic) was run as the mobile phase. The elution was performed at a flow 
rate of 1.0 ml/min and the analytical column was kept in a thermostated oven at 35 
ºC. The detection of INH was performed with Waters 2998 Photodiode Array 
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Detector at a set wavelength of 261 nm. The injection volume was 20 µl for all 
standards and samples. INH was eluted approximately 5.4 min after injection. A 
series of standard solutions of INH (100–1600 ng/mL) were prepared in milli Q 
water. The assay was linear (R
2
 > 0.99) for INH over the concentration range of 
200–1600 ng/ml. 
  Bioanalytical Method validation 
Method validation of INH in aqueous humor was carried out, following US Food 
and Drug Administration guidelines add year. The method was validated for system 
suitability, specificity, sensitivity, recovery, precision and accuracy, linearity and 
matrix effect of INH during sample processing. 
 
Preparation of the calibration curve in aqueous humor  
A five point calibration curve of INH was prepared by spiking 40 µl of blank 
aqueous humor with 10 µl each of the appropriate working dilution of INH to result 
in 600 to 1600 ng/ml of INH. 
High quality control (HQC: 1600 ng/ml), medium quality control (MQC: 1200 
ng/ml) and low quality control (LQC: 800 ng/ml) samples were prepared similarly 
for validation.  
 
System suitability 
System suitability was performed by determining AUC for the MQC (without 
spiking into aqueous humor) sample injected into the HPLC before the start of each 
analytical run and its comparison with the average AUC value obtained for the 
MQC, upon repetitive injections. 
 
Specificity 
Blank aqueous humor samples were prepared 
according to the sample preparation procedure described in experimental section. 
and screened for the presence of any interfering peaks corresponding to or near to 
the retention time of INH. 
 
Sensitivity 
The limit of quantification (LOQ) was taken as the lowest concentration in the 
standard curve with accuracy between 80–120% 
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and limit of detection (LOD) was determined at a signal to noise 
ratio (S/N) of 3 [16]. 
 
Recovery 
Recovery pertains to the extraction efficiency of an analytical method within the 
limits of variability. Recovery experiments was performed by comparing the 
analytical results for extracted samples at three concentrations (800, 1200, and 1600 
ng/ml) with the corresponding standards.  
 
Inter-day and intra-day precision and accuracy 
Inter-day and intra-day precision and accuracy were evaluated by spiking known 
concentration of INH in aqueous humor. The precision was expressed as % CV 
(coefficient of variation) and % accuracy was expressed by using the formula: 
measured concentration/nominal concentration × 100. 
Three different concentrations (LQC, MQC and HQC) were used and samples were 
prepared as per the procedures described above. Inter-day precision and accuracy 
were assessed over a period of 3 days using replicate (n=6) determinations for the 
spiked aqueous humor samples, whereas intra-day precision and accuracy were 
assessed on three separate occasions on the same day (n=6) for each concentration 
respectively. 
 
Pharmacokinetic studies 
Study design 
Male rabbits, weighing approximately 1.5 kg, were purchased from IMTECH 
(Chandigarh, India). Prior to experiments the rabbits were housed in standard cages 
and allowed free access to food and water. All the animal study protocols were 
approved by the Institutional Animals Ethics Committee, PU, Chandigarh (vide 
letter no. PU/IAEC/S/14/90). A total of 12 rabbits were used for the study. INH-SOL 
(n=6) and INH-SLNs (n=6) (150 µl
**
each; 150 µl x 14.32 mg/ml= 2.14 mg of INH) 
were instilled into one eye of each rabbit, keeping the other eye as control. Aqueous 
humor from dosed eye was withdrawn at 0.25, 0.5, 1, 2, 4, 8, 12, 24 and 48 h. The 
samples were collected and processed as described below. 
Aqueous humor from contralateral eye was also collected at some time points to 
confirm any systemic drainage of INH. 
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**
 Five 30 µl drops at 5 min intervals (150 µl) were instilled into each eye. Time of 
instilling last drop was taken as 0 time. 
 
Aqueous humor sampling 
After topical anaesthesia, the 26-gauge needle was inserted, just above the cornea- 
sclera limbus, so as to traverse through the centre of anterior chamber to withdraw 
aqueous humor. Around 100 µl of aqueous humor was withdrawn from each eye at 
every time-point. The aqueous humor was collected in polypropylene tubes and 
was labelled and stored at −20 °C until further analysis. 
   
Sample preparation (extraction procedure)  
To 50 µl of aqueous humor samples in an eppendorf tube, 450 µl of chloroform: 
methanol (3:1) was added. The sample was vortexed for 5 min and centrifuged at 
15,000 rpm to separate precipitated proteins. Supernatant, transferred to suitably 
labelled tubes, was evaporated to dryness on SPD speed Vac (Thermo Saavant add 
country etc) at a temperature of 50 ºC for 2 h; this step was repeated twice and the 
dried sample was reconstituted with 500 µl of MilliQ water. The sample was 
filtered through 0.2 µm syringe filter and was used for analysis using the developed 
HPLC method. Each sample was internally spiked with 4 µg/ml of INH so as to 
ensure detection of concentrations below limit of quantification (LOQ). All the 
conditions of HPLC were maintained the same as discussed earlier in section.  
  
Data Analysis 
The pharmacokinetic parameters were calculated using non-compartmental model. 
The area under the concentration–time curve from time zero to time t (AUC0-t) was 
calculated using the trapezoidal method. Peak concentration (Cmax) and the time at 
which the peak concentration is achieved (Tmax), were obtained directly from the 
individual concentration-time profiles. All values were corrected for the spiked 
concentration. The area under the concentration-time curve from time zero to 
infinity was calculated by: AUC0–∞= AUC0–t+ Ct/Ke, where Ct is the drug 
concentration observed at the last time and Ke is the apparent elimination rate 
constant obtained from the terminal slope of the individual concentration-time 
curves after logarithmic transformation of the concentration values and application 
of linear regression. The data obtained from pharmacokinetic parameters were 
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analyzed for statistical significance by a one way analysis of variance (ANOVA) 
followed by the Tukey’s test. 
 
Results and Discussion 
Preparation and characterization of INH-SLNs 
The INH-SLNs were prepared successfully and repetitively (n=6) by the 
microemulsion technique using Combi lipid, as the lipid core material and at a drug 
loading of 40% with respect to the lipid matrix. The samples were used as such 
without any further processing (viz. removing the free unentrapped drug from the 
samples) for all characterisation and evaluation parameters. 
 
Stability studies 
No significant change (p<0.05) in entrapment efficiency, total drug content and 
particle size of INH loaded SLN dispersion was observed upon storage under 
refrigeration for 6 months and 12 months, confirming their long term stability (Table 
1).  
Table 1 Stability study at 4±3 
o
C (n=6) 
 
 
 
 
 
 
 
 
 
Values are mean ± standard deviation. The results were analysed for statistical significance by a t test  
Values were not significantly different from one another, at p <0.05. 
 
Most nanostructured systems 
are recommended to be dialysed or lyophilized to retain their stability on 
storage. Such methods are (i) costly, (ii) time consuming (iii) may 
result in aggregates and microsized particles on reconstitution, and  
(iv) change the native milieu of nanoparticles, which may destabilize the system. The 
prepared aqueous SLN dispersion was stable for 1 year at 4 ºC. This may be attributed 
to the maintenance of SLNs in their native state in which they were produced [17] 
comprising suitable concentration of surfactants in the aqueous phase in which they 
remain dispersed even on long term storage. 
 
                                              % Change in parameters  
 Time  
(months) 
                             INH-SLNs 
TDC % EE % Particle size  
0 91.6 ± 3.40 65.2 ± 1.32 149.2 ± 4.90 
6 89.61± 2.90 64.75±0.87 153.8±8.60 
12 91.4 ± 4.64 66.4 ± 1.32 152.0 ± 0.18 
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In vitro release 
The release of drug from a matrix can be predicted based on the various drug release 
models and the release pattern can indicate the drug incorporation models. 
Five possible methods of drug release from SLNs is reported in the literature which 
are (a) desorption of drug bound to the surface, (b) diffusion through the nanoparticle 
matrix, (c) diffusion through the wall of nanocapsules, (d) nanoparticle matrix 
erosion, or (e) a combined erosion–diffusion process. 
Depending on the type of drug, incorporated amount, types and amounts of excipients, 
preparation technique and, environmental conditions during drug release as well as 
the geometry and dimensions of the nanoparticle, the drug release phenomenon may 
vary. 
The in vitro release profile of INH-SOL and INH-SLNs was obtained by the dialysis 
bag technique using simulated tear fluid (pH 7.2). All the INH from dialysis bag was 
released within 8 hours whil  INH-SLNs followed an extended released of upto 48 h 
(Figure 1) at which time 94% of the total INH was released. 
 
Figure 1: In vitro drug release of INH and INH-SLNs in simulated tear fluid (pH 
7.2). 
INH release increased exponentially and rapidly in the first 6 h (henceforth referred to 
as the “initial” release) from SLNs followed by a slower release over 48 h (henceforth 
referred to as the “sustained” release phase). It may however be noted that 28% drug is 
released at 4 h and 45% at 6 h. These values closely correspond to the free/unentrapped 
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drug present in the INH-SLN formulation. What is interesting is the fact that even this 
free/unentrapped INH is released from the SLNs at a rate much slower (though in a 
similar pattern) than the pristine drug, indicating that probably this amount is also 
loosely associated with the SLN particles.  
To suggest the mechanism of drug release, various release kinetic models were fitted to 
the obtained results. For the initial 8 h the Korsemeyer-peppas release model was the 
best fit model for both free INH and INH-SLNs. Peppas release exponent, n value, was 
0.85 indicating that the release of INH was governed by an “anomalous” process or non 
fickian diffusion. The anomalous transport could include both the drug diffusion and 
matrix swelling [18]. From 12 h to 48 h this diffusion controlled release was predicted 
to occur from a porous matrix as indicated by the Higuchi model. It seems that particles 
of drug closest to the surface of SLNs i.e. SLN shell are dissolved rapidly, generating 
numerous pores. Drug lying/entrapped within the core then diffuses to the surface and 
passes into the medium through pores the pores created on the surface such a 
mechanism is indicated for hydrophilic drugs. The factors affecting INH release form 
SLNs include presence of free drug in the surfactant coat as per its aqueous solubility 
and the later sustained release phase (8 h onwards) was due to the adsorption and 
encapsulation of drug within the lipid core.  
Ex-vivo corneal permeation 
INH-SLNs showed a significant improvement in apparent permeation coefficient (Papp) 
(2.2 fold), total amount permeated (1.6 fold) and percentage drug permeated (2.5 fold) 
at 6 h  as compared to free INH (INH-SOL) taken as control (Table 2; Figure 2). Ex-
vivo corneal permeation studies showed a significant improvement in flux (1.7 times) 
and total amount of INH permeated (0.24 mg/hr/cm
2
; 154 µg) when applied as INH-
SLNs versus INH-SOL (0.14 mg/hr/cm
2
; 91.0 µg). This enhanced permeation is due to 
the nanosize (149.2 nm) and composition of SLNs.  
The main characteristic of the epithelium is the presence of intercellular tight junctions 
(zonula occludens) that prevent the diffusion of hydrophilic macromolecules with size 
> 100 Da through the paracellular route [19]. In contrast, lipophilic substances, which 
readily diffuse through the lipid-based cell membranes, can pass through the epithelium 
via a transcellular route. The epithelial cells then act as reservoirs that slowly release 
these substances to the corneal stroma, indicating the feasibility of paracellular 
transport of developed INH-SLNs [20].    
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SLN formulation of INH showed high corneal transport. Latter can be attributed (i) 
encapsulation of INH into the lipophilic SLNs which would facilitate their transcellular 
transport through the cornea, (ii) presence of a (polysorbate 80), surfactant also helps in 
enhanced permeation. Latter may also have inhibitory effects on some drug efflux 
transporters (P-glycoproteins) [21, 22]. (3) Furthermore, the particulate nature of the 
formulation would ensure its adherence to the ocular surface and prevent tear washout 
of the drug. This will result in a sustained absorption and effect. 
 
       
 
Figure 2: Percentage amount of INH-SLNs and INH-SOL permeated through porcine 
cornea at various time intervals (n = 6).  
 
 
Table 2: Comparison of INH-SLNs with INH-SOL, in terms of total amount permeated, 
percentage permeation, steady state flux and apparent permeability coefficient (Papp) 
obtained during ex-vivo permeation studies using porcine cornea (n = 6). 
Formulation Total amount 
permeated in 6 h 
(µg) 
% Permeation Steady state 
flux 
(mg/hr/cm
2
) 
Apparent 
permeability 
coefficient 
Papp (cm/s) 
INH-SOL 91.0 ± 0.12 8.78 ± 1.20 0.14 ± 0.02 3.76 ± 0.53 
INH-SLNs 154.0 ± 0.08 22.04 ± 1.12 0.24 ± 0.01 8.17 ± 3.52 
Values are mean ± standard deviation. All the values between the two groups were significantly different from one another, at p < 
0.001, as per t- test 
Minimum Inhibitory Concentration 
The MIC values of INH, and INH-SLNs were found to be 0.5±0.01, and 0.098±0.003 
µg/ml respectively, against M. tuberculosis H37Rv (ATCC 25618) whereas the Blank-
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SLNs did not show any inhibition at the tested concentrations (Table 3). The MIC value 
of INH loaded SLNs was ~ 5 times less than INH-SOL. This further increased to 7.1 
times if free INH was removed from the SLNs. It may be concluded as also shown 
earlier that INH-SLNs enhance permeability of INH and hence the susceptibility of M. 
tuberculosis H37Rv to INH. MIC studies were also conducted on Blank-SLNs to ensure 
that the antibacterial effect was attributable to the INH in INH-SLNs and not to the 
nanocarrier itself. 
The strong antimycobacterial effect of INH-SLNs as compared to pristine INH also 
indicates enhanced uptake and intracellular retention by the Mycobacterium. The efflux 
inhibitor property of SLNs has also been suggested to increase the efficacy of drugs by 
increasing the amount of drug within the bacterial cells.  
 
Table: 3 Results of in vitro anti-tubercular assessment (MIC values) against 
Mycobacterium tuberculosis H37Rv by CFU (colony forming unit/ml) technique. 
 Minimum Inhibitory Concentration 
Formulation M. tuberculosis H37Rv (ATCC 25618) 
INH
*
 0.5±0.01 
Blank-SLNs - 
INH-SLNs (with 
free drug)
**
 
0.098±0.003 
INH-SLNs 
(without free 
drug)
**
 
0.07±0.003 
(-) No inhibition; Values are mean ± SD (mm) from the experiments in triplicate; Values of INH were significantly greater than 
those obtained for INH-SLNs, at p < 0.001 when t-test was applied. 
** Values were significantly different from one another, at p <0.001 when t-test applied  
 
Susceptibility of M. tuberculosis H37Rv  
Pristine INH, Blank-SLNs and INH-SLNs were appraised for the anti-tubercular 
activity using tubercular strain H37Rv. After 6 weeks of incubation period, the  
vials were visualized for any growth of the colonies at the tested concentrations. A dramatic 
decline in the number of colonies was observed at MIC. Blank-SLNs as expected did not 
show any inhibition as compared to positive control.  
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Figure 3: Susceptibility of M. tuberculosis H37Rv to kill. Control group (a), INH (b), 
Blank-SLNs (c), INH-SLNs (d), INH-SLNs (without free drug) (e). 
Mycobacterium tuberculosis, rely on lipids and on lipid membrane properties to gain 
access to their host cells, to persist in them (this also assigns resistance to them) and 
ultimately to egress from their hosts. Several mechanisms may be invoked to explain the 
influence of lipids on host-pathogen interactions during the various steps in the life cycle 
of M. tuberculosis [23]. To persist inside the phagosome, M. tuberculosis depends on 
host cholesterol. It has been shown that the mycobacterium uses cholesterol/ lipids either 
as an energy source or as a source of carbon [24].  
Hence the lipid based carrier, presently the SLNs, will attract the mycobacterium 
considering it a substrate. Once the lipid matrix of SLNs is degraded by the lipases 
produced by the mycobacterium, the encapsulated INH will be released right in its 
vicinity, producing an effective antibacterial action [25]. 
 
Cellular uptake 
The intracellular delivery of SLNs was followed first from the interaction of SLN with 
the cell membrane and then further uptake by the corneal and conjunctival cells. 
Fluorescein labelled SLNs was used to examine their ability to cross the cell membrane. 
In order to confirm the uptake, human conjunctival epithelium (HCJE) and human 
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corneal-limbal epithelial (HCLE) cells were incubated for 2 h with free fluorescein 
solution (F-SOL) and fluorescein loaded SLN (F-SLNs) (both were of same 
concentration) and the fluorescence intensity was measured by spectrofluorimeter after 
lysis of the cells (Figure 4). The control reading confirms that the cellular components 
itself do not show fluorescence that could potentially interfere with the results. A 
significantly higher uptake of F-SLNs in HCJE (1218.71 au and 10 times, respectively) 
and in HCLE cells (1166.21 au and 10.8 times, respectively), in comparison to F-SOL, 
was observed, establishing that SLNs impart an improved permeability to INH. 
 
 
Figure 4: Fluorescence intensity in HCLE (a) and HCJE (b) cells after incubation for 2h 
 
Ocular tissue distribution and fluorescence intensity 
It is generally observed that a topically dosed drug can transport to the interior of the 
eye via: (1) the transcorneal route which can be divided further into a) transvitreous 
route- where drug diffuses through the cornea, and enters the aqueous and the vitreous 
cavity; b) the uvea–scleral route where drug diffuses through the cornea, penetrates the 
aqueous humor, and continues through the uvea-scleral pathway and gains access to the 
choroid and retina; and the (2) periocular route (conjunctival uptake), where diffusion 
and absorption occurs via sclera.  
In present study the ocular drug distribution from SLNs was determined using 
fluorescein labelled SLNs (F-SLNs) and compared with fluorescein solution (F-SOL). 
The ocular sections were viewed under confocal microscope following their application 
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as drops. Overlay and confocal images confirm the presence of fluorescence upto 24 h 
after instillation of F-SLNs confirming significant and longer retention of the developed 
system in the ocular tissues including the internal eye tissue (Figure 5). Whereas the F-
SOL shows much lesser fluorescence intensity as compared to F-SLNs (Figure 6).  
 
Figure 5: Confocal images of ocular tissues 15 min (a), 30 min (b), 4h. (c), and 24h (d) 
after topical application of F-SLNs. What do different panels indicate First panel shows 
fluorescent image, middle panel shows image under bright light, and the last panel 
shows the overlay image. 
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Figure 6: Confocal images of ocular tissues 15 min (a), 30 min (b), 4 h (c), and 24 h (d) 
after topical application of F-SOL. First panel shows fluorescent image and last panel 
shows image under bright light, middle panel shows the overlay image. 
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Table 4: Fluorescent intensity of F-SOL and F-SLNs by using image J software 
Time (h) Intensity of F-SOL Intensity of F-SLNs 
0.25  2.30±4.23 9.88±12.65 
0.5 12.67±13.99 35.57±23.91 
4 1.30±4.9 12.90±10.15 
24 2.69±7.08 13.60±9.11 
  
 
 
Figure 7: Fluorescent images of ocular tissues of the eye at 15 min (a), 30 min (b), 4 h 
(c), and 24 h (d), post F-SLN administration. Fluorescent images of cryosectioned whole 
ocular tissues after F-SLN administration at 30 min (e). 
Confocal microscopy studies provided a direct evidence of the fact that the SLN system 
developed presently by us are capable of exporting the drug to ocular tissue in excess as 
compared to free solution which is observed in high fluorescent intensity upto 24 h in F-
SLNs in comparison to F-SOL samples. Further confirmation of cellular uptake studies 
was also revealed in HCLE and HCJE cell lines when strong fluorescence intensity was 
observed for F-SLNs treated cells. Human corneal epithelial cells are the first cells 
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encountered by a topically instilled eye drop. If a drug can penetrate the full thickness 
of cornea and reach the anterior chamber in high concentration, then further diffusion 
into the posterior chamber should occur easily.  
Transport of SLNs may occur by passive diffusion across the different compartments, 
although the presence of efflux transporters may also play a significant role and SLNs are 
known to overcome the various efflux transporters that are found in cornea.  
Fluorescent microscopy (whole eye section) also provides significant evidence that SLNs 
reach even upto the internal eye tissue. Furthermore, the interaction of SLNs with the 
glycoproteins of the cornea and conjunctiva can form a precorneal depot resulting in 
prolonged release of the encapsulated drug. All the more, the lipidic SLNs may  interact 
with the outer lipid layer of the tear film, increasing their residence in the conjunctival 
sac, where it either acts as a drug depot [26] or passively diffuses through the cornea 
intact. However, the stromal layer of the cornea is hydrophilic in nature. SLNs are lipidic 
particles dispersed in an aqueous surfactant solution, such that it depicts enhanced 
permeability both through the lipophilic and the hydrophilic physiological barriers. 
Inspite of showing effectiveness against the pulmonary and extrapulmonary 
mycobacterium infections, yet no ocular formulation of INH is in the market. In ocular 
drug delivery the major challenges are the structure of eye in which the epithelium is the 
outermost structure of the cornea and is composed of six cell layers. The main 
characteristic of the corneal epithelium is the presence of intercellular tight junctions 
(zonula occludens) that prevent the diffusion of hydrophilic molecules with size >100 Da 
through the paracellular route. In contrast, lipophilic substances, can readily diffuse 
through the epithelium via a transcellular route [27].  
 
Bioanalytical method development 
System suitability 
The system was found to be suitable for the determination of INH under the optimized 
chromatographic conditions. Average peak area per injection was determined at each 
time point and relative standard deviation (RSD) was ≤ 3.1% (data not shown). As per 
USFDA bio-analytical method validation guidelines, 2001, accuracy of the developed 
analytical procedure should be high and its RSD should be less than 5%. 
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The efficiency of the column was expressed by number of theoretical plates for the 6 
replicate injections and was above 8000 and USP tailing factor was below 1.5 for all 
the samples. As per HPLC method of analysis of INH defined by USP the number of 
theoretical plates should be >2500 and tailing factor <2.0. 
Specificity 
High specificity of the developed method was confirmed by the absence of any 
interfering peaks at the retention time of INH. Further, chromatograms obtained from 
spiked aqueous samples were found to be specific for INH (Figure 8 c). 
Sensitivity 
LOD and LOQ value for INH was 400 ng/ml and 600 ng/ml respectively. 
Recovery 
Recovery (n = 6) for INH was found to be 96.8 ± 4.9 %, 99.5 ± 11.0 % and 99.5 ± 5.0 
% for LQC, MQC, HQC samples, respectively. 
Intra- day and inter-day precision and accuracy 
The intra-day accuracy for INH was found to lie between 87.2–91.9 % in aqueous 
humor of rabbit samples with RSD less than 5% for the QC samples. 
The inter-day accuracy of INH in aqueous humor rabbit samples ranged from 89.0 % 
to 90.3 % for the QC samples. 
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Table 5: Inter-day precision and accuracy of INH in aqueous humor 
 
 
 
 
 
 
Table 6: Intra-day precision and accuracy of INH in aqueous humor 
 
 
 
 
 
 
 
Linearity 
The calibration curve for INH was found to be linear (r
2
 = 0.999) in aqueous humor at 
the concentration range of 600–1600 ng/ml. 
Nominal 
Concentration 
(ng/ml) 
Observed 
Concentration 
(ng/ml) 
% precision % accuracy 
Inter day 
LQC (800) 
 
712±28.6 4.0 89.0 
MQC (1200) 
 
1084±45.0 4.2 90.3 
HQC  (1600) 
 
1428±55.4 3.9 89.3 
Nominal 
Concentration 
(ng/ml) 
Observed 
Concentration 
(ng/ml) 
% precision % accuracy 
Intra day 
LQC (800) 
 
712.4±19.6 2.7 89.0 
MQC (1200) 
 
1103.2±17.1 1.5 91.9 
HQC  (1600) 
 
1406.4±26.9 1.9 87.2 
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Figure 8: HPLC chromatogram of INH (a), Blank aqueous humor (b), INH in aqueous 
humor (c). 
Pharmacokinetic parameters 
The concentration-time profiles and corresponding pharmacokinetic parameters of 
INH-SLN and INH-SOL after topical administration into the eye were monitored and 
determined in the aqueous humor. A significantly (p < 0.001) higher Cmax (1.5-fold) 
and bioavailability/AUC (427.6 % increase) for INH-SLN with respect to the INH-SOL 
was noted in aqueous humor. The concentration of INH in the aqueous humor in the 
SLN treated group was found to lie in the range of 23.31–2.10 µg/ml, over a 24 h 
period, which was several times higher than that observed for INH-SOL group (15.00–
2.02 µg/ml at 4 h). 
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Cmax of 23.31 µg/ml in aqueous humor progressively reduced to 16.37 µg/ml at 2 h 
followed by 12.5 µg/ml and 2.24 µg/ml at 4 and 24 h, respectively, indicating a 
sustained and prolonged stay of INH-SLNs in the aqueous humor as compared to INH-
SOL which reduced to 2.83 µg/ml at 4 h itself (Figure 9). 
 
Figure 9: Comparative concentration-time profile of INH-SLNs and INH-Sol in 
aqueous humor following topical application to rabbit eye 
 
Table 7: Pharmacokinetic parameters of INH-SLNs and INH-SOL following topical 
administration (n=6). 
Formulation Cmax Tmax (h) T1/2 (h) MRT (h) AUC (µg/ml) 
INH-SOL 15.09±3.10 0.25 4.69±0.17 6.19±0.37 44.00±4.62 
INH-SLNs 23.31±3.10 0.25 11.00±0.82 16.04±1.12 188.13±37.10 
Values are mean ± standard deviation. The results were analyzed for statistical significance by a t-test. All values observed for INH-
SLNs were significantly different from those for INH-Sol, at p < 0.001. 
Researchers have tried to deliver INH via various routes alternate to conventional route 
for treatment of pulmonary and extrapulmonary TB. T et al. (2015) tried to deliver the 
INH via transdermal route. 5% menthol, limonene or Transcutol
®
 were evaluated by 
these workers as the penetration enhancers. Menthol was not able to improve the 
absorption of INH. Transcutol
®
 reduced permeation flux (2.2-fold) but increased the 
amount of INH retained in the skin (1.7-fold). Limonene on the other hand was the most 
effective excipient since it increased permeation flux (1.5-fold) and lag time was greatly 
shortened (2.8-fold) [28]. Composite scaffold drug delivery system fabricated with an 
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isoniazid conjugated star poly (lactide-coglycolide) (PLGA-INH4) and β-TCP is also 
reported. INH concentrations were measured in tissues around implanted sites and in 
blood. In vivo release of INH at 4, 8 and 12 weeks post-surgery was evaluated. The 
concentration was found higher than minimal effective treatment concentration (5-10 
µg/mL) and a tissue concentration, 2-3 times higher than blood was observed [29]. We 
(Bhandari and Kaur, 2013) also reported a significant improvement (p<0.001) in relative 
bioavailability of INH-SLNs in plasma (6 times) and brain (4 times) after oral 
administration with respect to the free drug solution at the same dose.  
Ocular pharmacokinetic studies, presently, show 4.27 times higher bioavailability of INH 
when administered as SLNs versus the free drug solution in the aqueous humor. The 
longer ocular retention (2.6 times MRT) in aqueous humor is due both to the small size 
of SLNs and presumed retention in mucopolysaccharide chains of mucin available in the 
precorneal area allowing extended permeation in to the aqueous humor. Another point, 
which is noteworthy in the study, is the fact that peak effects were obtained within (0.25 
h is 15 min) min after administration of the last drop of SLNs. This indicates a fast 
passage of the developed system across various barriers to reach the aqueous humor. 
This will ensure quick control of infection. 
Conclusions: Presently reported INH-SLN system can offer a local and efficient control 
of ocular TB without demonstrating side effects associated with the oral therapy.   
Highly water soluble drug was efficiently incorporated in SLNs through 
microemulsification and shows better corneal permeation. Corresponding safety in 
corneal and conjunctival cell lines followed by in vivo acute and subchronic toxicity 
studies in rabbits establish suitability of developed SLN formulation for ocular use. 
Significant uptake of fluorescein labelled SLNs in corneal and conjunctival and ocular 
tissues following topical administration as drops, gives the direct evidence of their 
efficient target ability. Improved localised concentration of INH in aqueous humor will 
result in effective treatment. 
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Supplementary Data 
Development of isoniazid loaded solid lipid nanoparticles for ocular delivery with proof of 
concept: In vitro characterization, antimycobacterial, pharmacokinetics and safety evaluation. 
 
Mandeep Singh, Ana Isabel Guzman Aranguez, Afzal Hussain, Cheerneni Sai Srinivas, 
Indu Pal Kaur 
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Characterisation of INH-SLNs 
Developed INH-SLNs were characterised exhaustively for TDC, EE, particle size and 
zeta potential. Morphological characterization was done using AFM and TEM, 
followed by DSC, FTIR and NMR 
 
Total drug content (TDC) and entrapment efficiency (EE)                                                                                                                   
SLN dispersion (0.1 ml) was treated with 5 ml mixture of chloroform: methanol (3:1) 
and diluted with water upto 10 ml in 15 ml centrifuge tube. The tube was shaken to 
mix the contents and centrifuged at 9000 rpm for separation of water and chloroform 
layer. The water layer was collected and diluted suitably to measure the total drug 
content by HPLC. Chloroform helps to dissolve the lipid matrix and disrupt the 
formed SLNs. 
EE was determined by adding 1M magnesium sulphate to INH-SLN dispersion (1 ml) 
in eppendorf tube followed by vortexing. The dispersion was then centrifuged at 
15000 rpm for 15 min to separate the flocculated SLNs from free drug in the 
supernatant. INH was determined by HPLC in both the pellet (entrapped drug) and the 
supernatant (unentrapped/ free drug). 
 
Particle size and zeta potential 
Mean diameter of SLNs in the dispersion (10X dilution) was determined using photon 
correlation spectroscopy at an angle of 15, 30 and 160 degree having laser diodes 658 
nm as light source and zeta potential was determined by forward scattering through 
transparent electron technology using flow cell assembly (Beckman Coulter, Delsa 
nano C).  
 
Atomic force microscopy 
Atomic force microscopy studies were performed using AFM apparatus (JPK 
Instruments, Germany).  An Intermittent contact mode (ICM) in air atmosphere, at the 
ambient pressure (about 760 mm of Hg) and temperature (20 ºC) was used to reduce 
the deformation of the sample that occurs while scanning in contact mode. A 20 µl 
droplet of INH-SLN sample, diluted 200X times in water, was used to deposit on 
silicon surface. All the measurements were performed immediately after the water 
evaporation. A rectangular AR5-NCLR (NANOSENSORS) silicon n-cantilevers, 
~165 kHz and ~48 N/m, with a nominal tip radius less than 15 nm, were used. AFM 
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defines the surface morphology of particles by means of the topography and ICM 
phase data. All AFM images were analysed using JPK data processing software.  
 
Morphological evaluation using transmission electron microscopy (TEM)   
For observation under TEM, INH-SLNs after suitable dilution (20X) with distilled 
water were stained with 2% phosphotungstic acid (PTA) in phosphate buffer (pH 6.8) 
for 5 min, after which the excess PTA was removed. Sample was spread on a carbon 
coated copper grid which was then observed under TEM (FE Teenai G2 F20, 
Netherlands) at a voltage of 120 kV, for morphological parameters like size, 
sphericity and aggregation. 
 
FTIR 
FTIR spectra of Combi lipid (1:4 combination of stearic acid and Compritol 888 
ATO
®
), INH, Blank SLNs (SLNs prepared without drug), and INH-SLNs were 
recorded using KBr pellet technique on an IR spectrophotometer (Perkin Elmer, 
USA). 
 
Powder X-ray diffraction (PXRD) 
The crystalline/amorphous nature of INH-SLNs was confirmed by X-ray diffraction 
measurements using X-ray diffractometer (XPERT-PRO, PANalytical). PXRD 
studies on INH and lyophilised Blank SLNs and INH-SLNs were performed by 
exposing the samples to CuKα radiation (45 kV, 40 mA) and scanning from 5º to 50º, 
2θ at a step size of 0.017º and scan step time of 25 second. Obtained PXRD patterns 
were compared with the characteristic drug peak intensity obtained from INH.  
 
Differential scanning calorimetry (DSC) 
DSC thermograms of Combi-lipid, INH, INH-SLNs and blank SLNs were recorded 
on Q20 Differential Scanning Calorimeter. Weighed quantity (2 mg) of each 
component was added to aluminium pans and heated at predetermined rate of 10 
ºC/min over the temperature range of 30 to 300 ◦C in presence of nitrogen. Thermal 
data analysis of thermograms was conducted using TA instruments universal analysis 
2000 software. The recorded scans were plotted between heat flow (W/g) and 
temperature. The calibration of calorimeter was performed using Indium as a 
standard. 
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Nuclear magnetic resonance (NMR) spectroscopy 
1
H NMR spectra were recorded by an Avance II 400 spectrometer (Bruker, 
Rheinstatten, Germany), operating at 400MHZ. Aliquots of INH, Blank-SLNs, and 
INH-SLN dispersion was filled in NMR tube. Accurate quantity of deuterated water 
was added for field login and tetramethylsilane (TMS) was added as reference for 0 
ppm. 
 
Safety of INH-SLNs 
A two tier invitro toxicity dermal toxicity (preamble to ocular toxicity) and/acute 
ocular toxicity evaluation of INH-SLNs were done in rabbits as per OECD. Further 
repeat dose (5 times) and chronic repeat dose (one week) study was also conducted in 
rabbits as per previously reported procedure [1]. Details of these studies are included 
in the supplementary data. Any adverse effects of INH-SLNs on ocular tissue was 
also confirmed under the ocular tolerance study. 
Cytotoxicity studies 
The viability of stratified HCLE (human corneal - limbal epithelial), and HCJE 
(human conjunctival epithelial) cell lines exposed to INH-SLNs was determined by a 
cell proliferation assay using MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide). Cells grown in keratinocyte serum-free medium (Invitrogen, 
Carlsbad, CA) and supplemented with 25 µg/ml bovine pituitary extract, 0.4 mM 
CaCl2, 0.2 ng /mL epidermal growth factor (EGF) and suitable antibiotics were 
maintained at 37 ºC in 5% CO2. For efficient stratification and differentiation, upon 
reaching confluence, the culture medium was replaced with Dulbecco’s minimal 
essential medium (DMEM)/F12 medium supplemented with 10% calf serum and 10 
ng/ml EGF for 7 days [2].  
Stratified HCLE and HCJE cells in DMEM/F12 medium were exposed for 24 h to 
various samples viz. INH-SOL, Blank-SLNs and INH-SLNs at a concentration of 
1µg/ml and 10 µg/ml. After exposure, MTT test was used to assess cellular viability 
as described previously [3]. Briefly, fresh MTT solution (0.5 mg/ml) was added to 
cells, which were then incubated for 2 h at 37 ºC. Following incubation, cells were 
lysed and the released purple formazan was dissolved in dimethyl sulfoxide. 
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Absorbance of the samples was read using Gen 5 plate reader (BioTek, Winooski, 
VT, USA) at 570 nm and corrected for background by subtracting the absorbance at 
690 nm from that at 570 nm. The mean absorbance values of non-treated cells were 
taken as 100% and results are expressed as percentage cell viability compared to the 
control (non-treated) cells. Experiments were performed in triplicate.    
Dermal irritation/corrosion test as per OECD guideline 404 (ADI, 2002) 
This test was conducted to confirm the safety of the formulation for dermal 
application. According to OECD guideline 405, the in vivo eye irritation/corrosion 
test, should preferably be preceded by a study establishing the in vivo dermal safety 
(OECD testing guideline 404) as a preamble to ocular toxicity studies [4]. 
Young female albino rabbits of age around 6 months (weight of 1.3-1.7 kg) with 
intact skin were used in the study. Fur was removed from the dorsal trunk area of the 
test animal using hair clippers followed by the application of a hair removing cream, 1 
day before the test. INH-SLNs (0.5 ml) applied uniformly onto a 6 cm
2 
gauze patch 
were applied to the cleared skin and fixed with non-irritating tape. First patch was 
removed after 3 min, and if no reaction was observed then a second patch was applied 
for 1 h. In case of the absence of any reaction the study was extended for a period of 4 
h. Good contact of the test formulation with the skin was ensured. Application site 
was so selected that the access of the animal to the patch was limited so that ingestion 
of the patch was not possible. Some shaved skin area near the test area was reserved 
as control. At the end of the test, the gauze patch was removed, and the skin was 
examined 4 h after patch removal, for signs of erythema and redness as described 
previously [1]. The test was performed first on a single animal and its response 
graded. Once the test on first animal showed absence of irritation/corrosion, the 
negative response was confirmed using two additional animals. 
Eye irritation/corrosion test as per OECD guideline 405 (AEI, 2002)  
INH-SLN dispersion (0.1 ml) was instilled in the conjunctival sac of the right eye of 
each rabbit (n=3) once and also five times at regular (5 min) intervals (for repeat test) 
by gently pulling the lower lid to create space for instillation. Left eye served as a 
control in each case. The eyes were examined regularly at 1, 24, 48, and 72 h after 
application of the test drops and scored as per the scale described in the OECD 
guidelines [1, 5]. A chronic repeat dose study in which the test formulation was 
Page 32 of 53
https://mc04.manuscriptcentral.com/fm-nnm
Nanomedicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
instilled five times (at 5 min interval) every day in the conjunctival sac of rabbits, for 
a period of one week, was performed to establish the safety for long term therapy [1]. 
Ocular tolerance evaluation 
To examine the effects of INH-SLNs on ocular structure and integrity, the left eyeball 
was removed from rat eyes 0.5 h, 1 h and 2 h post administration of SLNs to the left 
eye of the rat. Right eye of these animals was taken as control. The eye balls were 
washed with saline and fixed with 8% v/v formalin solution. The material was 
dehydrated with an alcohol gradient, put in melted paraffin and solidified in block 
form. Cross-sections (<5 µm) were cut, stained with haematoxyline and eosine (H and 
E) and microscopically observed (Nikon eclipse 90i, Japan) for any pathological 
effects.  
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Result and Discussion 
Total drug content (TDC) and entrapment efficiency (EE) 
The drug content of the developed INH-SLNs was 14.50±0.54 mg/ml which was 
91.6±3.4% of what was originally incorporated (16 mg/ml) and the EE was 
65.2±2.2% (n=6).  
Note: Previously prepared INH-SLNs by our group [6] were loaded with 10% INH 
with respect to the lipid matrix, though it showed higher EE of > 80%.  
 
Particle size and zeta potential 
The developed INH-SLNs showed an average particle size (n=6) of 149.2 ±4.9 nm 
and PDI of 0.15±0.02 (n=6) (Figure S1). The zeta potential was found to be -0.35 ± 
0.28 mV (Figure S2).  
Liposomes with a size of 105–125 nm were found to reach the retina whereas the 
corresponding micrometer size liposomes did not show significant penetration [7]. 
Nano-sized particles are also reported to show better bioadhesion [8] and greater 
surface for association with the cornea and conjunctiva. They can also pass across 
the anatomical constraints of the eye and provide enhanced penetration through the 
cornea[9, 10]. Nanoemulsions interact with the lipid layer of the tear film, remaining 
in the conjunctival sac for longer times, and consequently acting as a drug depot 
[11]. Similarly, the nanoparticulate nature of SLNs will also impart an increased 
residence time on the ocular surface in turn enhancing permeability and hence ocular 
bioavailability. An increase in particle size from 48.4 nm reported previously 
(Bhandari and Kaur 2013) to the present value of 149.2 nm is attributed to 4 times 
increase loading of INH (from 10% to 40%) presently. An increase in size with 
increase in loading of drug is also reported elsewhere [12]. 
The near neutral zeta of SLN dispersion guarantees a physical stability of the 
colloidal dispersion. As per the DLVO (named after inventors Derjaguin, Landau, 
Verwey and Overbeek) theory, the colloid stability depends on the sum of Van der 
Waals attractive forces and electrostatic repulsive forces due to the electron double 
layer [13]. While zeta potential provides information on the electrostatic repulsive 
forces it does not provide any insight on the attractive Van der Waals forces. 
Therefore, it is not uncommon to come across stable colloids with low zeta and vice 
versa. The same is reported by us earlier also for the preparation of rifampicin SLNs 
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(−3.5 ± 0.80), ethambutol SLNs (-5.6± 0.90) and ketoconazole SLNs (3.19) in our 
lab [1, 14]. 
Tween 80 used presently as an emulsifier for production of INH-SLNs is non-ionic 
in nature. It is however indicated that non-ionic surfactants assign a negatively 
charged interface at neutral pH as seen presently. This was attributed to differential 
absorption of hydroxyl and hydronium ions on the interface [15]. 
 
 
 
Figure S1: Particle size distribution of a representative INH-SLNs batch 
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Figure S2: Zeta Potential of one batch of INH-SLNs 
 
Particle size and zeta potential in biological fluids 
The average particle size and PDI of developed INH-SLNs in simulated tear fluid 
(STF; pH 7.2) [16] increased to almost a double size (316.5±8.7 nm) with PDI, 
0.24±0.22. The size also increased significantly to 231.4±5.3 nm with PDI 
0.35±0.01 at pH 7.4 in PBS.  
The zeta potential however did not change significantly (P≤0.15) both in STF 
(+0.24±0.2 mV) and PBS at pH 7.4 (-0.11±0.04 mV). 
The significant increase in particle size in STF and at pH 7.4 is due to the presence 
of electrolyte salts in these fluids. The smallest particle size and narrow size 
distribution was achieved in electrolyte free aqueous SLN suspension [15]. Presence 
of electrolytes trigger destabilisation of SLN dispersion by reducing the electrostatic 
repulsive force between the particles resulting in their coalescence to form bigger 
particles [17]. It is also indicated that near zero charge (as is the case presently; zeta 
potential of aqueous INH-SLNs dispersion is -0.35 mV) dispersion coalescence 
more easily [18]. 
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           Atomic force microscopy (AFM) 
Topographic AFM images of formulated SLNs showed a diameter of 800 nm, and a 
height of 75 nm (Figure S3). 
Size was larger than that observed by PCS technique and TEM. It may be due to 
sample preparation for AFM, when bulk water molecules although removed by 
evaporation at 25 ºC over a 24 h can result in practically hydrated SLNs which show a 
size larger than their actual size. 3D cross-section images (Figure S3) confirm a 
matrix structure for the SLNs, mechanically resistant to collapse. Nevertheless, a 
flattening of SLNs by probe impact may account not only for a reduced height but 
also increase in the diameter of the SLNs due to a probe flattening effect [19]. 
 
Figure S3: Atomic force microscope images of a INH-SLNs (a) topographic image 
(vertical status-bars are representing the height data); (b) and (c) pseudo-3D 
topographic images of a single particle at different angles. 
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Transmission electron microscopy 
Morphological analysis of INH-SLN in aqueous dispersions, detected by TEM 
analysis, indicate polyhedral to spherical particles varying from 63 - 117 nm (Figure 
S4) in size. Average particle size obtained with dynamic light scattering (DLS) was 
149.2 nm; DLS measures hydrodynamic diameter which is usually more than the 
actual particle size [20]. 
 
 
 
Figure S4: HRTEM images of INH-SLNs 19000X (a) and (b) at 200kv 
 
Particle shape is a crucial parameter, exerting significant impact on cellular uptake, 
uptake kinetics and mechanism, intracellular distribution and cytotoxicity of 
nanoparticles. The order of cellular uptake of nanoparticles is reported as sphere 
>cube > rod > disk, probably due to ease of bending of cell membrane around the 
particles. The study revealed that the, spherical shape seems more favourable to 
improve the efficacy of the cargo [21].  
The polymorphic form of SLNs also reflects in the shape of the particles; particles in 
α modification form are usually observed circular to polyhedral [22]. 
 
FTIR studies 
The FTIR spectrum of pure isoniazid exhibited characteristic peaks of carbonyl C= O 
bond (1666 cm
−1
), amino group NH2 (1331 cm
−1
), N-N single bond (1219 cm
−1
), N-H 
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bending (1554 cm
−1
), C-H bond of the aromatic ring (3015 cm
−1
), and C-C=O 
bending (671 cm
−1
). Combi lipid exhibited characteristic peaks at 2919 cm
−1 
and 2850 
cm
−1
 (alkanes stretch) and 1741 cm
−1
 (C=O ester stretch).  Blank-SLNs also exhibited 
the same characteristic peaks but with reduced intensity as compared to the pure lipid. 
However, there is a change in the CH assymetric stretch from 2850 for the lipid 
combination to 2857 cm
−1 
in both blank and INH-SLNs (Figure S5). 
 
Figure S5: FTIR spectra of Combi-lipid, INH, Blank-SLNs, INH-SLNs, Stearic acid, 
Compritol
®
888 ATO (COMP) and the INH SLNs stored at 2-8 ºC for 6 months (INH-
SLN stability). 
 
  In SLNs, the vibrational modes due to functional groups particularly, the stretching 
oscillations provide information about the conformation (Trans gauche) dynamics and 
type of crystallographic subcell. The lipid polymorphs of crystalline or quasi crystalline 
structures display the lateral packing which is characterized as highly ordered all trans- 
confirmation of the polymethylene chain. The hydrocarbon chain-melting phase 
transitions are accompanied by the broadening of all IR-active bands and by an overall 
decrease in their amplitudes as observed presently for the Blank and INH-SLN spectra 
with respect to bulk lipid. The methylene symmetric stretching (sνCH2) and methylene 
antisymmetric stretching (asνCH2) vibrations give rise to IR-active bands centred near 
2850 cm
−1
 and 2919.27 cm
−1
, respectively as seen with Combi lipid. The conformational 
disordering of an all-trans polymethylene chain is accompanied by an upward shift in the 
sνCH2 IR band maxima by almost 7 cm
−1 
as is
 
observed for the IR spectra of both Blank 
and INH-SLNs. This reflects a probable hydrocarbon chain conformational disorder. 
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Although the 2920 and 2850 cm
−1
 IR absorption bands can both be used to monitor 
hydrocarbon phase transitions, but the 2920 cm
−1
 band is rarely used in practice. This is 
because the asνCH2 band contains significant overlapping contributions from CH3 
groups and is even perturbed by Fermi resonance interactions with the first overtones of 
the CH2 scissoring vibration [23, 24]. The IR band at 2850 cm
−1
 is usually not perturbed 
by these factors and under most circumstances arises predominantly from the symmetric 
C-H stretch of the CH2 group. SLN formulations are hallmarks of a collective trans-
gauche isomerization of the glyceride alkyl chains. This alteration in lipid conformation 
will lead to lattice imperfections as observed by the qualitative upward shifts of the peak 
contours detected for the C-H bands at 2857 cm
−1
. Former would allow better and greater 
entry or encapsulation of drug in the free space generated between the disrupted fatty 
acid chains. The INH-SLNs show an almost similar spectrum even after storage for 6 
months under refrigerated conditions, confirming absence of any phase inversion in the 
samples (Figure S5). Latter is the most important concern with SLN formulations [25].  
XRD studies 
Powder X-ray diffraction study of pristine drug (INH), Combi lipid, lyophilized Blank-
SLNs and INH-SLNs was performed to confirm the amorphous or crystalline nature of 
SLNs (Figure S6). INH showed peaks at 2θ value of 11.9, 15.5, 16.5, 19.5, 23.8, 25.0 
and 40.2. Combi-lipid showed sharp peaks at 2θ value of 21.2 and 23.3. Blank SLNs 
however did not show any peak corresponding to these values except small peaks at 2θ 
scattering angle of 4.8. INH-SLNs did show some peaks at 2θ scattering angle of 15.9, 
19.4 and 23.7 (may be due to the un-entrapped/ free drug ~35 % in the INH-SLN 
dispersion. Free drug was not removed from the SLN formulation). The peak intensities 
of SLNs were however weak, small and diffuse indicating an amorphous or at the most 
only a partially recrystallized lattice. The stability sample of INH-SLN (6 month) did not 
show any difference from the fresh INH-SLN sample. 
The chance for efficient incorporation of drug is known to decrease with increasing 
crystal lattice and polymorphic transition to a stable β
/
 or β form, which can result in 
sustained expulsion of the drug upon storage. However since the XRD pattern of the 
stability samples of INH-SLN is equally diffuse with no observable, new crystalline 
peaks it may be concluded that the drug is not expulsed from the SLNs during storage 
(Figure S7). Latter is also confirmed by no significant change in the value of EE of 
stored INH-SLN samples (Table 1). 
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Figure S6: Powder X-ray diffraction patterns of INH (a), Combi-lipid (b), Blank-SLNs 
(c), INH-SLNs (d), INH-SLNs (Stability sample) (e). 
 
Differential scanning calorimetry (DSC) of SLNs 
The DSC profiles of the developed formulation and bulk lipid often show their 
thermal behaviour which is influenced by their crystallinity. The heating (or melting) 
of lipid and cooling (or recrystallization) of the hot lipid emulsion to form SLNs can 
lead to changes in the crystallinity and polymorphic form of a lipid. DSC is a 
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characterization technique which was performed presently to investigate the 
crystallinity of lipid in SLNs. The DSC profile of bulk Combi lipid (a combination of 
Compritol 888 ATO
®
 and Stearic acid) shows a sharp melting transition at 73.67 ºC, 
also represented as Tmax in Table S1.  
 
Table S1: Differential scanning calorimetry (DSC) data of SLNs 
Sample Tonset (ºC) Tmax  (ºC) ∆H (J/g) 
Combi-Lipid 72.22 73.67 55.50 J/g 
Blank SLNs 71.33 76.76 64.67 J/g 
INH-SLNs 70.74 71.53 0.46  J/g 
Stability sample 69.38 72.01 15.47 J/g 
 
Thermal behaviour of Blank-SLNs and INH-SLNs is shown in (Figure S7). INH-
SLNs show a melting endotherm at 71.53 ºC corresponding to the Combi lipid at 
73.67 ºC, whereas Blank SLNs show an upstream shift of the endotherm to 76.76 ºC 
but with broad peak intensity. Latter indicates the amorphousness of a less ordered 
crystal structure. The reduction in crystallinity would imply opportunity for successful 
incorporation of drug in the lipid matrix. The lower Tmax of INH loaded SLNs with a 
significantly lower enthalpy as compared to both bulk Combi-lipid and Blank SLNS 
indicate high incorporation of drug into the SLNs. Incorporation of a drug into the 
lipid matrix increases the imperfections in crystal of lipid with more imperfections 
requires less energy which leads to decrease in melting enthalpy of the SLNs. Since 
size of the SLNs was < 200 nm, hence an energetically suboptimal state is created due 
the high surface energy associated with nanoparticles. This causes a reduction in the 
melting point of the lipid (as observed for INH-SLNs) due to the “Gibbs-Thomson” or 
“small size” effect [25-28]. It is also implied, that the reduction of particle size and 
crystallinity, leads to ‘missing neighbours of the crystalline arrangement’ that lead to 
weaker Van der Waals interactions and thus to a reduced Gibbs free energy of the 
lattice that results in a drop in the melting temperature with decreasing particle size. 
The lipidic nanoparticles are usually more or less polydisperse thus the melting 
transition is not only shifted to lower temperatures but is also broadened since the 
fractions of different particle sizes melt at different temperatures. Similar behaviour of 
lower melt temperature and enthalpy continues to be observed in thermogram of the 
INH-SLNs stored for 6 months (stability sample).  
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Figure S7: Thermogram of INH (a), Combi-lipid (b), Blank-SLNs (c), INH-SLNs (d), 
INH-SLNs (stability). 
 
1
H NMR Studies 
Following NMR spectra were obtained for various components of INH-SLNs and the 
Blank and INH-SLN formulations: 
INH - (400MHz, D2O) δ 7.4 (2.0H, s), 8.4 (2H, s) 
Combi Lipid - (400MHz, CDCl3) δ 0.8 (3H, m), 1.6 (31H, s), 2.2 (2H, d) 
Phospholipon
®
 
1
H - (400MHz, D2O) δ 2.1, 3.1 (4H, d), 3.5 (2H, d), 3.6 (1.7H, s), 3.7 
(1H, d) 
Tween 80 - (400MHz, D2O) δ 0.8(0.73, s), 1.2(18H, s), 1.2(3H, s), 1.8 (4H, s), 
2.2(3H, s), 3.5(70H, s). 
Blank-SLNs - (400MHz, D2O) δ 0.5 (0.2 H, d) δ 0.9 (1H, d), 3.3 (4H, s) 
INH-SLNs - (400MHz, D2O) δ 0.7 (6H, d), δ 1.1(35H, d), δ 1.4 (3.6H, s), δ 1.8 (5.5, 
s), δ 2.1 (3.7 H, s), δ 3.5 (125H, s), δ 7.5 (2.0H, d), δ 8.5(2.0H, d). 
1
H NMR spectra of INH, Combi lipid, Phospholipon
®
 90H (Soya 90H), Tween 80, 
Blank-SLNs and INH-SLNs are shown in (Figure S8). 
1
H NMR can be used 
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efficiently to gain information on the molecular mobility and on material viscosity 
consequently. In the extreme limit for a completely solidified matrix, peak broadening 
or no signal (non-mobility) is expected to appear in the spectra recorded under 
aqueous dispersion of SLNs. 
The main resonance regions observed in SLNs is as follows: (i) 0.7–2.1 ppm range, 
reflecting the methyl 
protons of the saturated aliphatic chains; (ii) 3.0–5.0 ppm range attributed to the 
protons of CH, 
CH2, CH3 groups belonging to glycerol, ethylene glycol (PEG) and 
choline/ethanolamine moieties; and (iii) 5.0–6.0 ppm region, 
for which signals of methine protons owing to trigliceridyl moiety 
and unsaturated fatty acid chains are detected. The signal corresponding to Tween 80 
at 3.5 ppm appears as a specific singlet in both blank and INH-SLNs (3.3 ppm for 
blank SLNs, 3.5 for INH-SLNs) indicating its presence in the SLN shell.  The INH 
signals are detected at 7.4 ppm and 8.4 ppm and were fairly seperate. The signals of 
INH in INH-SLNs (δ 7.5 ppm and δ 8.5 ppm) were observed. This may either be due 
to higher drug payload which is present in the shell, [29] or due to unentrapped INH 
(35 %). The INH signal in SLN showed lower amplitude with broader lines, which 
could be attributed to the strong interaction between the INH molecule and the lipid 
indicating restricted mobility of INH in SLNs [30]. The broad resonance signals in 
0.7–2.1 ppm range in INH-SLNs indicates highly restricted mobility of the 
acylglycerol molecule of lipid as compared to the sharp signals obtained for the 
Combi lipid.  
The Phospholipon
®
 90H peak at 2.1 ppm however either disappeared in Blank or 
showed a weak signal in INH-SLNs indicating its incorporation between the Tween 
80 outer layer and the lipid core of SLNs. 
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Figure S8: NMR spectra of INH (a), Tween 80 (b), Combi lipid (c), 
Phospholipon
®
 90H (d), Blank-SLNs (e), INH-SLNs (d). 
The absence of or weakening of Phospholipon
®
 90H signal indicates a strong 
interaction of its functional groups with the solid Combi lipid as observed in the 
mobility of its functional group. This reduced or no signal in contrast to the strong 
signal for Tween 80 in INH-SLNs indicates its attachment but not incorporation into 
the lipid core material, since a weak signal is still observed [31]. The surfactant tail 
groups in the lipid emulsion are likely to be packed tightly together at the oil–water 
interface, thus forming a relatively rigid ‘‘shell” surrounding the encapsulated lipid 
droplets at high surfactant concentrations as for Tween 80 (27 %) in presently 
prepared INH-SLNs using microemulsification technique. In such cases, the 
surfactant restricts the molecular motion of the triacylglycerol molecules of the lipid 
within the droplet interior [32]. However, Tween 80 shows a distinct peak in the 
NMR spectra of INH-SLNs indicating its presence in the shell and may be in the outer 
aqueous region as free surfactant due to its higher concentration. 
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Cytotoxicity studies 
Cytotoxicity of the developed formulation was checked in both HCJE and HCLE cell 
lines. The concentration of 1 µg/ml and 10 µg/ml was selected for the study. No 
statistically significant (P<0.05) cytotoxicity was observed for Blank-SLNs and INH-
SLNs in comparison to control when administered to HCJE and HCLE cells at these 
concentrations after incubation for 24 h (Figure S9).  
 
Figure S9: % Cell viability in HCJE and HCLE cells at varying concentration after 
incubation for 24 h. 
Dermal irritation studies 
The score for dermal irritation/corrosion study are compiled in Table 2. Figure S10 
shows the skin of test animals, photographed before and after application of the 
formulation. Zero scores clearly demonstrate a non-irritating/corrosive nature of 
developed SLNs when applied to dermal tissues, and hence we proceeded to the eye 
irritation test (section 3.5) in accordance with OECD guidelines.  
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 Figure S10 Skin surface of rabbit (a) before application of the formulation and (b) after 
application. 
Table S2:  Acute dermal irritation/corrosion study of INH-SLNs in rabbits. 
 
  
DERMAL 
 
 
 
Scores of rabbit 1  Scores of rabbit 2  Scores of rabbit 3   
Score Time (h)   
 
0 
h 
1 
h 
24
h 
48
h 
72
h 
0 
h 
1 
h 
24
h 
48
h 
72
h 
0 
h 
1 
h 
24
h 
48
h 
72
h 
Erythmea 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/40 
Odema 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/40 
Total score 0/80 
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Acute eye irritation/corrosion test  
Single instillation study 
Zero scores established that developed SLN system is safe for ocular delivery after 
single instillation (Table 3). There were no sign of irritation/corrosion in any ocular 
tissue. 
Table S3:  Single instillation acute eye irritation/corrosion study of INH-SLNs in rabbit 
eye. 
 
Repeated instillation study 
This study is a modification or extension of the previous study and was performed in 
view of the fact that it is usually recommended to frequently repeat the instillation of 
ocular formulations. Similar studies have been reported by us earlier [33]. The zero 
scores obtained from this study (Table S4) prove the system to be safe for repetitive 
ocular use too. 
 
  
Ocular 
tissue 
Scores of rabbit 1  Scores of rabbit 2  Scores of rabbit 3   
Score Time (h)   
0 
h 
1 
h 
24
h 
48
h 
72
h 
0 
h 
1 
h 
24
h 
48
h 
72
h 
0 
h 
1 
h 
24
h 
48
h 
72
h 
Cornea  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0/60  
Iris  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0/30  
Conjunctiva  0  0  0  0  0  0  0  0  0  0  0  0  1  1  0  0/45  
Chemosis 0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0/60  
Total score 0/195 
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Table S4: Repeat instillation acute eye irritation/corrosion study of INH-SLNs in rabbit 
eye. 
 
Chronic repeat instillation irritation/corrosion test 
The treatment of Mycobacterium infection may involve therapy for longer periods, so 
we evaluated the developed formulation for chronic repeat instillation (5 times at 5 
minute interval) for a period of one week. Compilation of scores (zero value) 
demonstrate the SLN disperse system to be non-irritant/corrosive upon chronic use for 
upto 7 days to all ocular tissues, and are concluded to be safe for chronic ocular use 
(Table S5). 
  
Ocular 
tissue 
Scores of rabbit 1  Scores of rabbit 2  Scores of rabbit 3   
Score Time (h)   
0 
h 
1 
h 
24
h 
48
h 
72
h 
0 
h 
1 
h 
24
h 
48
h 
72
h 
0 
h 
1 
h 
24
h 
48
h 
72
h 
Cornea  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0/60  
Iris  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0/30  
Conjunctiva  0  0  0  0  0  0  0  0  0  0  0  0  1  1  0  0/45  
Chemosis 0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0/60  
Total score 0/195 
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Table S5:  Scores of chronic repeat instillation irritation/corrosion study INH-SLNs 
 
Ocular safety studies of the developed system were performed to evaluate its efficacy 
by using cell viability assays, histological studies and in vivo experiments. Due to more 
Ocular tissue  Cornea  Iris  Conjunctiva  Chemosis Score  Total Score  
    r
a
b
b
it 1
  
0h 0  0  0  0   
 
 
 
  0/104 
  
1d 0  0  0  0   
 
 
 
 
 
 
 
 
 
 
 
 
    0/312 
  
2d 0  0  0  0  
3d 0  0  0  0  
5d 0  0  0  0  
6d 0  0  0  0  
7d 0  0  0  0  
          r
a
b
b
it 2
  
0h 0  0  0  0   
 
 
 
  0/104 
  
1d 0  0  0  0  
2d 0  0  0  0  
3d 0  0  0  0  
5d 0  0  0  0  
6d 0  0  0  0  
7d 0  0  0  0  
          r
a
b
b
it 3
  
0h 0  0  0  0   
 
 
 
  0/104 
  
1d 0  0  0  0  
2d 0  0  0  0  
3d 0  0  0  0  
5d 0  0  0  0  
6d 0  0  0  0  
7d 0  0  0  0  
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common anatomical and biochemical features of rabbits eye with human eye, it was 
used as the animal of choice [34].  
Ocular tolerance evaluation 
Corneal, retinal and conjunctival cross-sections were evaluated, post administration of 
INH-SLNs in rat eyes for their influence, if any, on cell structure and tissue integrity. 
Results confirmed absence of any adverse effects on tissue integrity. The tissue 
appeared normal and no signs of inflammation such as accumulation of macrophages, 
and lymphocytic infiltrate were observed (Fig.13). The developed formulation left the 
tissue structure and integrity visibly unaffected. Results confirm good ocular 
biocompatibility of the developed formulation. 
 
Figure S11: Optical microscopic pictures showing histological section of rat eye 
Naïve control represented in (a) retina and sclera at 10X (b) at 40X. (c)- (h) represent conjunctival tissue 
of test animals at 30 min (c and d), 1 h (e and f) and 2 h (g and h).  
 
 
 
Page 51 of 53
https://mc04.manuscriptcentral.com/fm-nnm
Nanomedicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
References 
 
Kakkar S, Karuppayil SM, Raut JS, et al., Lipid-polyethylene glycol based nano-ocular 
formulation of ketoconazole. Int J Pharm. 2015;495:276-289 
Gipson IK, Michaud SS, Argueso P, et al., Mucin gene expression in immortalized human 
corneal-limbal and conjunctival epithelial cell lines. Invest Ophthalmol Vis Sci. 
2003;44:2496-2506 
Guzman-Aranguez A, Calvo P, Ropero I and Pintor J, In vitro effects of preserved and 
unpreserved anti-allergic drugs on human corneal epithelial cells. J Ocul Pharmacol 
Ther. 2014;30:790-798 
OECD, 2015. Test No. 404: Acute Dermal Irritation/Corrosion, OECD Paris. 
OECD, 2017. Test No. 405: Acute Eye Irritation/Corrosion, OECD, Paris. 
Bhandari R and Kaur IP, A Method to Prepare Solid Lipid Nanoparticles with Improved 
Entrapment Efficiency of Hydrophilic Drugs Curr Nanosci. 2013;9:211-220 
Hironaka K, Inokuchi Y, Tozuka Y, et al., Design and evaluation of a liposomal delivery 
system targeting the posterior segment of the eye. J Control Release. 2009;136:247-253 
Yoncheva K, Lizarraga E and Irache JM, Pegylated nanoparticles based on poly(methyl 
vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive 
properties. Eur J Pharm Sci. 2005;24:411-419 
Shen Y and Tu J, Preparation and ocular pharmacokinetics of ganciclovir liposomes. 
AAPS J. 2007;9:1-7 
Nagarwal RC, Kant S, Singh PN, Maiti P and Pandit JK, Polymeric nanoparticulate 
system: a potential approach for ocular drug delivery. J Control Release. 2009;136:2-
13 
Alany RG, Rades T, Nicoll J, Tucker IG and Davies NM, W/O microemulsions for ocular 
delivery: evaluation of ocular irritation and precorneal retention. J Control Release. 
2006;111:145-152 
Shah RM, Eldridge DS, Palombo EA and Harding IH, Microwave-assisted formulation of 
solid lipid nanoparticles loaded with non-steroidal anti-inflammatory drugs. Int J 
Pharm. 2016;515:543-554 
Missana T and Adell A, On the applicability of DLVO theory to the prediction of clay 
colloids stability. J Colloid Interface Sci. 2000;230:150-156 
Singh H, Bhandari R and Kaur IP, Encapsulation of Rifampicin in a solid lipid 
nanoparticulate system to limit its degradation and interaction with Isoniazid at 
acidic pH. Int J Pharm. 2013;446:106-111 
Choi KO, Aditya NP and Ko S, Effect of aqueous pH and electrolyte concentration on 
structure, stability and flow behavior of non-ionic surfactant based solid lipid 
nanoparticles. Food Chem. 2014;147:239-244 
Liu Y, Liu J, Zhang X, et al., In situ gelling gelrite/alginate formulations as vehicles for 
ophthalmic drug delivery. AAPS PharmSciTech. 2010;11:610-620 
Cui Z, Shi KZ, Cui YZ and Binks BP, Double phase inversion of emulsions stabilized by a 
mixture of CaCO3 nanoparticles and sodium dodecyl sulphate. Colloids Surf A 
Physicochem Eng Asp. 2008;329:67-74 
Freitas C and Müller RH, Stability determination of solid lipid nanoparticles (SLN) in 
aqueous dispersion after addition of electrolyte. J Microencapsul. 1999;16:59-71 
Dubes A, Lopez HP, Abdelwahed W, et al., Scanning electron microscopy and atomic 
force microscopy imaging of solid lipid nanoparticles derived from amphiphilic 
cyclodextrins. Eur J Pharm Biopharm. 2003;55:279-282 
Damari SP, Shamrakov D, Varenik M, et al., Practical aspects in size and morphology 
characterization of drug-loaded nano-liposomes. Int J Pharm. 2018;547:648-655 
Page 52 of 53
https://mc04.manuscriptcentral.com/fm-nnm
Nanomedicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Li Y, Kroger M and Liu WK, Shape effect in cellular uptake of PEGylated nanoparticles: 
comparison between sphere, rod, cube and disk. Nanoscale. 2015;7:16631-16646 
Bunjes H, Steiniger F and Richter W, Visualizing the structure of triglyceride 
nanoparticles in different crystal modifications. Langmuir. 2007;23:4005-4011 
Brubach JB, Jannin V, Mahler B, et al., Structural and thermal characterization of 
glyceryl behenate by X-ray diffraction coupled to differential calorimetry and 
infrared spectroscopy. Int J Pharm. 2007;336:248-256 
Lewis RNAH and McElhaney RN, Membrane lipid phase transitions and phase 
organization studied by Fourier transform infrared spectroscopy. Biochim Biophys 
Acta. 2013;1828:2347-2358 
Bunjes H and Unruh T, Characterization of lipid nanoparticles by differential scanning 
calorimetry, X-ray and neutron scattering Adv Drug Deliv Rev. 2007;59:379–402 
Unruh T, Bunjes H, Westesen K and Koch MHJ, Investigations on the melting behaviour 
of triglyceride nanoparticles. Colloid Polym Sci. 2001;279:398-403 
Bunjes H, Koch MHJ and Westesen K, Effect of Particle Size on Colloidal Solid 
Triglycerides. Langmuir. 2000;16:5234-5241 
Hunter RJ, Foundations of Colloid Science. Clarendon Press, Oxford. 1993;1:267–269 
Westesen K, Bunjes H and Koch MHJ, Physicochemical characterization of lipid 
nanoparticles and evaluation of their drug loading capacity and sustained release 
potential. J Control Release. 1997;48:223-236 
Ali H, El-Sayed K, Sylvester PW and Nazzal S, Molecular interaction and localization of 
tocotrienol-rich fraction (TRF) within the matrices of lipid nanoparticles: Evidence 
studies by Differential Scanning Calorimetry (DSC) and Proton Nuclear Magnetic 
Resonance spectroscopy (
1
H NMR). Colloids Surf B Biointerfaces. 2010;77:286-297 
Schubert MA, Harms M and Müller-Goymann CC, Structural investigations on lipid 
nanoparticles containing high amounts of lecithin. Eur J Pharm Sci. 2006;27:226-236 
Helgason T, Awad TS, Kristbergsson K, McClements DJ and Weiss J, Effect of surfactant 
surface coverage on formation of solid lipid nanoparticles (SLN). J Colloid Interface 
Sci. 2009;334:75-81 
Kaur IP and Kakkar S, Nanotherapy for posterior eye diseases. J Control Release. 
2014;193:100-112 
Zernii EY, Baksheeva VE, Iomdina EN, et al., Rabbit Models of Ocular Diseases: New 
Relevance for Classical Approaches. CNS Neurol Disord Drug Targets. 2016;15:267-
291 
 
 
Page 53 of 53
https://mc04.manuscriptcentral.com/fm-nnm
Nanomedicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
